+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Deal-Making Trends in Pharma - Thematic Research

  • PDF Icon


  • 56 Pages
  • September 2019
  • Region: Global
  • GlobalData
  • ID: 4850403
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Deal-Making Trends in Pharma - Thematic Research


To gain a better understanding of the pharmaceutical deal landscape, this report will dive into three separate deal categories: strategic partnerships, licensing activity, and M&A activity. Furthermore, the categories will be further broken down by four dominating therapeutic themes. These include gene therapy, immuno-oncology, microbiome, and orphan drugs.

These themes are among those expected to have the greatest presence in deals made within the pharmaceutical industry, which is indicative of the optimism surrounding their future potential. Please also note that this report only covers select geographies, North America, Europe, and Asia-Pacific, the three regions with the highest deal volume and value. These regions were also chosen to be covered in this report based on the fact that they are hotspots for the development of innovative drugs.
This report also identifies target drug companies that would be strong acquisition target candidates.

The companies identified include those that have drugs that fall into one of the four major themes discussed in this report: gene therapy, immuno-oncology, microbiome, and/or orphan drugs. Chosen targets were also selected on the basis of having drugs in both the preclinical stage and clinical stage settings. Identified targets are also all privately owned, and have seen little to no recent merger and acquisition (M&A) activity in the past five years. Lastly, the list of targets also includes those have had recent positive clinical trial data.


The author’s Deal-Making Trends in Pharma report provides with in-house expertise to provide an assessment of the deal landscape within the pharmaceutical industry.

Components of the report include -
  • Data analysis, trends, and insights for strategic partnerships, licensing activity, and M&A activity within the pharmaceutical industry
  • Data analysis, trends, and insights for deals that encompass specific therapeutic themes (gene therapy, immuno-oncology, microbiome, and orphan drugs)
  • Data analysis, trends, and insights for deals that have occurred in select geographies (North America, Europe, and Asia-Pacific)
  • Identification of drug companies that would be strong acquisition target candidates

Reasons to Buy

  • Gain a better understating of the volume and value dynamics within the pharmaceutical deal space.
Develop and design your corporate strategies through an in-house expert analysis of deals impacting the healthcare industry.
  • Stay up to date on the industry’s most impactful deals that have been completed within the past 5 years, along with a glimpse of deals completed or to be completed in 2019.
  • Identify emerging deal trends, as they relate to deal type, therapeutic theme, geography, to gain a competitive advantage.
  • Identify drug companies that would be strong acquisition target candidates.

Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Deal-Making and the Importance of Themes
3.1 Huge Deals in 2019
3.1.1 Takeda Acquires Shire
3.1.2 Bristol-Myers Squibb Acquiring Celgene
3.2 Strategic Partnerships
3.3 Licensing Agreements
3.4 Mergers and Acquisitions
3.5 Gene Therapy
3.6 Immuno-Oncology
3.7 Microbiome
3.8 Orphan Drugs
3.9 Geographical Breakdown and Comparison
4 Strategic Partnership Activity over the Last Five Years
4.1 A Closer Look at Partnership Activity (key themes and factors driving deals)
4.1.1 Gene Therapy
4.1.2 Immuno-Oncology
4.1.3 Microbiome
4.1.4 Orphan Drugs
4.2 Valuations
4.3 Case Studies
4.3.1 Gene Therapy
4.3.2 Immuno-Oncology
4.3.3 Microbiome
4.3.4 Orphan Drugs
5 Licensing Activity over the Last Five Years
5.1 A Closer Look at Licensing Activity (key themes and factors driving deals)
5.1.1 Gene Therapy
5.1.2 Immuno-Oncology
5.1.3 Microbiome
5.1.4 Orphan Drugs
5.2 Valuations
5.3 Case Studies
5.3.1 Gene Therapy
5.3.2 Immuno-Oncology
5.3.3 Microbiome
5.3.4 Orphan Drugs
6 Merger and Acquisition Activity over the Last Five Years
6.1 A Closer Look at Merger and Acquisition Activity (key themes and factors driving deals)
6.1.1 Gene Therapy
6.1.2 Immuno-Oncology
6.1.3 Microbiome
6.1.4 Orphan Drugs
6.2 Valuations
6.3 Case Studies
6.3.1 Gene Therapy
6.3.2 Immuno-Oncology
6.3.3 Microbiome
6.3.4 Orphan Drugs
7 What Does It Mean?
7.1 Strategic Partnerships
7.2 Licensing Agreements
7.3 Mergers and Acquisitions
8 Outlook for Deal-Making in Pharma
9 Appendix: Our “Thematic” Research Methodology
9.1 Deals and Thematics Analysis Methodology
9.2 Viewing the world’s data by themes makes it easier to make important decisions
9.3 Traditional Thematic Research Does a Poor Job of Picking Winners and Losers
9.4 Introducing Thematic Engine
9.5 This is how it works
9.6 How Our Research Reports Fit Into Our Overall Research Methodology
9.7 About the Author
9.8 Contact us
9.9 Disclaimer
List of Tables
Table 1: Top 20 Strategic Partnerships (by value)
Table 2: Top 20 Licensing Agreements (by value)
Table 3: Top 20 Mergers and Acquisitions (by value)
Table 4: Company Targets
List of Figures
Figure 1: Strategic Partnerships Deal Volume*
Figure 2: Licensing Agreements Deal Volume*
Figure 3: M&A Deal Volume*
Figure 4: Gene Therapy Deals
Figure 5: Immuno-Oncology Deals
Figure 6: Microbiome Deals
Figure 7: Orphan Drugs Deals
Figure 8: Partnerships Deal Geography 2014 to H1 2019*
Figure 9: Licensor HQ*
Figure 10: Licensee HQ*
Figure 11: Acquisitions Deal Geography 2014 to H1 2019*
Figure 12: Gene Therapy Partnerships
Figure 13: Immuno-Oncology Partnerships
Figure 14: Microbiome Partnerships
Figure 15: Orphan Drugs Partnerships
Figure 16: Gene Therapy Licensing Agreements
Figure 17: Immuno-Oncology Licensing Agreements
Figure 18: Microbiome Licensing Agreements
Figure 19: Orphan Drugs Licensing Agreements
Figure 20: Gene Therapy M&A Deals
Figure 21: Immuno-Oncology M&A Deals
Figure 22: Microbiome M&A Deals
Figure 23: Orphan Drugs M&A Deals
Figure 24: Acquirer Venn Diagram
Figure 25: Five-Step Approach for Generating a Sector Scorecard